Page last updated: 2024-12-04

bumetanide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2471
CHEMBL ID1072
CHEBI ID3213
SCHEMBL ID27525
MeSH IDM0003024

Synonyms (218)

Synonym
bumetanida
bumetanidum
ro-10-6338
chebi:3213 ,
CHEMBL1072
s-95008.
ro-106338
s95008.
MLS001148265
AB00052253-15
AB00052253-16
BRD-K38197229-001-06-7
MLS000028457 ,
KBIO1_000034
DIVK1C_000034
3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid
EU-0100162
bumetanide, >=98%
segurex
benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-
einecs 249-004-6
cambiex
c17h20n2o5s
bumex
bumetanidum [inn-latin]
aquazone
lixil-leo
bumethanide
brn 2185351
fontego
bumetanida [inn-spanish]
burinex
fordiuran
butinat
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
pf 1593
benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl-
lunetoron
yurinex
diurama
SPECTRUM_001317
BSPBIO_000152
BSPBIO_001508
BSPBIO_003061
28395-03-1
PRESTWICK_679
NCGC00015149-02
BIO1_000421
BIO1_001399
BIO2_000228
BIO1_000910
cas-28395-03-1
lopac-b-3023
NCGC00015149-01
BIO2_000708
IDI1_033978
PRESTWICK3_000276
SPECTRUM5_001212
SMP1_000049
BPBIO1_000168
PRESTWICK2_000276
LOPAC0_000162
IDI1_000034
cid_2471
bdbm25903
AB00052253
bumetanide ,
3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid
DB00887
3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
bumex (tn)
bumetanide (jp17/usp/inn)
D00247
ro 10-6338
NCGC00022072-05
NCGC00022072-07
NCGC00022072-04
smr000058418
KBIOSS_000228
KBIO3_000456
KBIO3_000455
KBIOGR_000439
KBIOSS_001797
KBIO2_006933
KBIO3_002561
KBIO2_001797
KBIO2_002796
KBIO2_005364
KBIO2_004365
KBIO2_000228
KBIOGR_000228
PRESTWICK1_000276
SPECTRUM2_001050
SPECTRUM4_000030
PRESTWICK0_000276
NINDS_000034
SPECTRUM3_001481
SPBIO_000980
SPBIO_002371
SPECTRUM1502004
NCGC00022072-06
NCGC00022072-08
NCGC00015149-03
NCGC00022072-03
NCGC00015149-06
HMS2089P13
HMS1989L10
B 3023 ,
HMS2092N03
NCGC00015149-12
HMS500B16
HMS1791L10
HMS1361L10
HMS1921B20
HMS1568H14
HMS3260B05
HMS3259O08
HMS2095H14
A819434
pharmakon1600-01502004
nsc-758145
nsc758145
dtxcid702699
dtxsid5022699 ,
tox21_110088
HMS2230P15
CCG-40125
NCGC00015149-13
NCGC00015149-04
NCGC00015149-07
NCGC00015149-09
NCGC00015149-10
NCGC00015149-11
NCGC00015149-05
NCGC00015149-08
0y2s3xuq5h ,
bumetanide [usan:usp:inn:ban:jan]
nsc 758145
unii-0y2s3xuq5h
burine
lixil
3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic acid
NCGC00015149-15
LP00162
bumetanide [ep impurity]
bumetanide [who-dd]
bumetanide [usp-rs]
bumetanide [mart.]
bumetanide [ep monograph]
bumetanide [usp monograph]
bumetanide [inn]
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid.
bumetanide [usan]
bumetanide [jan]
bumetanide [vandf]
bumetanide [mi]
bumetanide [orange book]
S1287
AKOS015896600
gtpl4837
HMS3374E02
HY-17468
CS-1821
NC00550
SCHEMBL27525
NCGC00015149-16
tox21_110088_1
KS-5211
3-butylamino-4-phenoxy-5-sulphamyl-benzoic acid
3-n-butylamino-4-phenoxy-5-sulfamyl-benzoic acid
3-n-butylamino-4-phenoxy-5-sulphamyl-benzoic acid
NCGC00260847-01
tox21_500162
bumetanide, british pharmacopoeia (bp) reference standard
bufenox
HMS3402L10
AB00052253_17
OPERA_ID_1734
AB00052253_18
mfcd00078949
bumetanide, european pharmacopoeia (ep) reference standard
bumetanide (ro 10-6338)
AC-8115
SR-01000003062-2
sr-01000003062
bumetanide, united states pharmacopeia (usp) reference standard
HMS3654B13
J-017055
SR-01000003062-7
SR-01000003062-4
SBI-0050150.P003
HMS3712H14
SW196834-3
Q275926
Z1541758727
ro 10-6338; pf 1593 pound>>ro-10-6338; pf1593 pound>>ro10-6338; pf-1593
BCP28485
BRD-K38197229-001-17-4
EN300-122330
HMS3873C13
SDCCGSBI-0050150.P004
NCGC00015149-26
ro 10-6338;pf 1593
3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoic acid
bumetanide; 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid; benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-; benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl- (8ci); 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid; 3-(butylamino)-4-ph
82U ,
bumetanide in bulk
bumetanida (inn-spanish)
bumetanide (usan:usp:inn:ban:jan)
bumetanide (mart.)
bumetanide (ep monograph)
bumetanide (ep impurity)
bumetanidum (inn-latin)
bumetanide (usp-rs)
bumetanide (usp monograph)
c03ca02

Research Excerpts

Overview

Bumetanide is a loop diuretic that is proposed to possess a beneficial effect on disorders of the central nervous system, including neonatal seizures. It acts as an inhibitor of sodium-potassium-chloride cotransporter 2 (NKCC2) and its isoform NKCC1.

ExcerptReferenceRelevance
"Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). "( Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol.
Bruining, H; Cristian, G; Geertjens, L; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M, 2022
)
2.44
"Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC. "( Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020
)
2.39
"Bumetanide is a loop diuretic that is proposed to possess a beneficial effect on disorders of the central nervous system, including neonatal seizures. "( Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate.
Abduljalil, K; Boylan, GB; Cryan, JF; Donovan, MD; Griffin, BT, 2018
)
2.15
"Bumetanide is a potent loop diuretic that acts as an inhibitor of sodium-potassium-chloride cotransporter 2 (NKCC2) and its isoform NKCC1. "( Bumetanide attenuates acute lung injury by suppressing macrophage activation.
Huang, KL; Hung, CM; Peng, CK; Wu, CP, 2018
)
3.37
"Bumetanide is a specific Na+-K+-Cl- co-transporter inhibitor which can maintain chloride homeostasis in neurons."( Bumetanide: A review of its neuroplasticity and behavioral effects after stroke.
Liu, F; Qu, H; Sun, X; Tao, D; Xiao, T; Zhao, C; Zhao, M; Zhao, S; Zhou, Z, 2019
)
2.68
"Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions."( Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Ben-Ari, Y; Damier, P; Hammond, C,
)
2.3
"Bumetanide is a specific inhibitor of this cotransporter."( Age- and dose-specific anticonvulsant action of bumetanide in immature rats.
Mares, P, 2009
)
1.33
"Bumetanide is a loop diuretic used clinically to treat heart failure, acute renal failure, high blood pressure, and edema. "( Detection of bumetanide in an over-the-counter dietary supplement.
Borges, CR; Crouch, DJ; Hoggan, AM; Shelby, MK; Slawson, MH,
)
1.94
"Bumetanide is a recently introduced diuretic that inhibits sodium transport in the thick ascending limb of the loop of Henle. "( Bumetanide: a new loop diuretic (Bumex, Roche Laboratories).
Halstenson, CE; Matzke, GR, 1983
)
3.15
"Bumetanide is a potent 'loop' diuretic for the treatment of oedema associated with congestive heart failure, hepatic and renal diseases, acute pulmonary congestion and premenstrual syndrome and in forced diuresis during and after surgery. "( Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
Heel, RC; Ward, A, 1984
)
3.15
"Bumetanide is a recently developed natriuretic and diuretic agent, belonging to the "loop" class of diuretics. "( Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic.
Flamenbaum, W; Friedman, R,
)
1.82
"Bumetanide is a potent diuretic drug which has some structural features in common with furosemide. "( Potassium chloride cotransport in steady-state ascites tumor cells. Does bumetanide inhibit?
Aull, F, 1981
)
1.94
"Bumetanide is a potent loop diuretic that acts at the ascending loop of Henle and proximal renal tubule blocking sodium reabsorption. "( Intramuscular bumetanide and furosemide in congestive heart failure.
Abrams, J,
)
1.93
"Bumetanide is a loop diuretic that is used for the treatment of edema and hypertension. "( Influence of protein and calorie malnutrition on the pharmacokinetics and pharmacodynamics of bumetanide in rats.
Kim, SH; Lee, MG, 1993
)
1.95
"Bumetanide is a weak organic acid which is transported into hepatocytes by a transport system that is related neither to the cloned sodium-dependent taurocholate cotransporting polypeptide Ntcp nor to the cloned organic anion transporting polypeptide oatp. "( What we have learned about bumetanide and the concept of multispecific bile acid/drug transporters from the liver.
Blumrich, M; Brühl, B; Eckhardt, U; Föllmann, W; Honscha, W; Horz, JA; Müller, N; Nickau, L; Ottallah-Kolac, M; Petzinger, E; Platte, HD; Schenk, A; Schuh, K; Schulz, K; Schulz, S, 1996
)
2.03
"Bumetanide is a new diuretic, which acts in the ascending limb of Henle's loop. "( [Bumetanide, a new diuretic active during chronic renal failure (author's transl)].
Beroniade, V; Coy, JL; Delavelle, F; Fries, D, 1976
)
2.61
"Bumetanide was found to be a potent oral natriuretic agent without producing changes in either GFR or effective renal plasma flow."( Effectiveness of bumetanide in nephrotic syndrome: a double-blind crossover study with furosemide.
Agus, ZS; DeFronzo, R; Goldberg, M; Lau, K; Morrison, G; Rascoff, J, 1976
)
1.32
"Bumetanide2 is a new diuretic with a rapid onset and short duration of action. "( Bumetanide: A preliminary report of its pharmacological properties and therapeutic efficacy in oedema.
Avery, GS; Brogden, RN; Speight, TM, 1975
)
3.14
"Bumetanide proved to be a highly effective diuretic, irrespective of time of administration."( Patient tolerance of long-term diuretic/potassium supplement therapy.
Singh, BB; Watt, DA, 1976
)
0.98
"Bumetanide is a potent diuretic. "( Analysis of bumetanide in human urine by high-performance liquid chromatography with fluorescence detection and gas chromatography/mass spectrometry.
Billay, DM; Chan, SC; Gradeen, CY,
)
1.95
"Bumetanide is a potent inhibitor of cation-chloride co-transport systems in many cell types, including duck red cells. "( [3H]bumetanide binding to duck red cells. Correlation with inhibition of (Na + K + 2Cl) co-transport.
Forbush, B; Haas, M, 1986
)
2.27
"Bumetanide is a potent displacer of bilirubin and should be used with caution in jaundiced neonates."( The bilirubin-displacing capacity of bumetanide in critically ill neonates.
Shankaran, S; Walker, PC, 1988
)
1.27

Effects

Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models. The potential to curtail growth of the tumor vasculature can be employed in future therapeutic strategies.

ExcerptReferenceRelevance
"The bumetanide ELISA has an I-50 for the parent drug of about 2.0 ng/mL and will detect bumetanide or its metabolites for about 8 hours in urine after intravenous administration of a 1.7-mg dose per horse."( Immunoassay detection of drugs in racing horses: detection of ethacrynic acid and bumetanide in equine urine by ELISA.
Blake, JW; Chang, SL; Goodman, JP; Henry, PA; Kwiatkowski, S; Stanley, S; Tai, HH; Watt, D; Wood, T; Woods, WE,
)
0.84
"Bumetanide (BU) has potential efficacy against cytotoxic oedema."( Bumetanide Rescues Aquaporin-4 Depolarization via Suppressing β-Dystroglycan Cleavage and Provides Neuroprotection in Rat Retinal Ischemia-Reperfusion Injury.
Chen, C; Fan, P; Gan, S; Hu, J; Huang, J; Lu, W; Qiu, G; Ran, J; Xu, J; Xu, S; Xue, K; Zhang, L, 2023
)
3.07
"For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetanide impossible."( The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B, 2023
)
1.39
"Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models. "( Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios.
Dai, Y; Deng, S; Du, X; Feng, J; Huang, CC; Ji, Y; Li, F; Lin, CP; Luo, Q; Sahakian, BJ; Shen, C; Tang, Y; Wang, K; Xu, M; Yu, J; Zhang, L, 2020
)
2.23
"Bumetanide has anxiolytic effects in rat models of conditioned fear. "( Bumetanide blocks the acquisition of conditioned fear in adult rats.
Amstislavskaya, TG; Ko, MC; Lee, MC; Lu, KT; Tang, TH; Tikhonova, MA; Yang, YL, 2018
)
3.37
"Bumetanide has been reported to attenuate ischemia-evoked cerebral edema. "( Bumetanide protects focal cerebral ischemia-reperfusion injury in rat.
He, Y; Huang, H; Huang, J; Ruan, L; Wang, G, 2014
)
3.29
"Bumetanide has the potential to curtail growth of the tumor vasculature and can be employed in future therapeutic strategies."( Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
Haaga, J; Jin, E; Lu, ZR; Malamas, AS; Zhang, Q, 2015
)
1.44
"Bumetanide has demonstrated efficacy in the management of edema associated with congestive heart failure, hepatic cirrhosis, and renal insufficiency."( Bumetanide: a new loop diuretic (Bumex, Roche Laboratories).
Halstenson, CE; Matzke, GR, 1983
)
2.43
"Bumetanide has also been shown effective in treating edema due to renal disease, even when modest to severe renal insufficiency is present, and it may be useful in the treatment of edema refractory to other loop diuretics."( Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic.
Flamenbaum, W; Friedman, R,
)
1.1
"Bumetanide has brought about a significative reduction of the right pressures and of resistances both in pulmonary and systemic circulations, without any effect on ventricular function indexes."( [Hemodynamic changes produced by intravenous bumetanide in congestive heart failure].
Lomanto, B; Rossi, A; Ziacchi, V, 1981
)
1.24
"The bumetanide ELISA has an I-50 for the parent drug of about 2.0 ng/mL and will detect bumetanide or its metabolites for about 8 hours in urine after intravenous administration of a 1.7-mg dose per horse."( Immunoassay detection of drugs in racing horses: detection of ethacrynic acid and bumetanide in equine urine by ELISA.
Blake, JW; Chang, SL; Goodman, JP; Henry, PA; Kwiatkowski, S; Stanley, S; Tai, HH; Watt, D; Wood, T; Woods, WE,
)
0.84
"Bumetanide has outgrown to become a tool for physiologists and pharmacologists in renal transport research."( [The loop diuretic bumetanide as a tool in physiology and pharmacology].
Petzinger, E, 1992
)
1.33

Actions

Bumetanide is shown to increase renal blood flow and to augment the proportion of the cortical blood flow to middle cortex. It can produce a previously unobserved lowering of IOP when the Na+/H+ antiport is also inhibited.

ExcerptReferenceRelevance
"Bumetanide, with 7 times lower affinity for carbonic anhydrase and 14-40 times higher inhibition of renal electrolyte transport processes than furosemide, did not decrease CSF flow."( The effect of furosemide and bumetanide on cerebrospinal fluid formation.
Langham, MR; Vogh, BP, 1981
)
1.28
"That bumetanide can produce a previously unobserved lowering of IOP when the Na+/H+ antiport is also inhibited substantiates a dominant antiport mechanism."( Inhibitors of NHE-1 Na+/H+ exchange reduce mouse intraocular pressure.
Avila, MY; Civan, MM; Seidler, RW; Stone, RA, 2002
)
0.77
"Bumetanide is shown to increase renal blood flow and to augment the proportion of the cortical blood flow to middle cortex. "( Renal cortical blood redistribution after bumetanide related to heterogenicity of cortical prostaglandin metabolism in dogs.
Ahnfelt-Ronne, I; Olsen, UB, 1976
)
1.96
"Bumetanide caused an increase in unbound bilirubin concentration at drug concentrations of 0.5-50 micrograms/ml."( The bilirubin-displacing capacity of bumetanide in critically ill neonates.
Shankaran, S; Walker, PC, 1988
)
1.27

Treatment

Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC. Treatment may help diminish the adverse effects of initial treatment with insulin/saline.

ExcerptReferenceRelevance
"Bumetanide treatment of apoE4 mice without or with Aβ accumulation rescued electrophysiological, pathological, or cognitive deficits."( Experimental and real-world evidence supporting the computational repurposing of bumetanide for
An, A; Balestra, ME; Bicak, M; Chang, W; Chaudhry, F; Chen, B; Chen, N; Choudhary, K; De Freitas, J; Glicksberg, BS; Grone, B; Hao, Y; Huang, Y; Jones, EAA; Kosti, I; Koutsodendris, N; Nova, P; Oskotsky, T; Paranjpe, I; Pineda, S; Sirota, M; Taubes, A; Wang, C; Yoon, SY; Zalocusky, KA; Zilberter, MY, 2021
)
1.57
"Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC. "( Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020
)
2.39
"Bumetanide treatment significantly reduced average pain intensity according to the NRS and the short form of the McGill Pain Questionnaire scores. "( Preliminary study of analgesic effect of bumetanide on neuropathic pain in patients with spinal cord injury.
Behzad, E; Gharaylou, Z; Hadjighassem, M; Hosseindoost, S; Majedi, H; Nasirinezhad, F; Ramezani, F; Shafaghi, L; Zarepour, L, 2020
)
2.27
"Bumetanide treatment was then continued for 6 months."( A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Agah, E; Aghamollaii, V; Gharaylou, Z; Hadjighassem, M; Kebriaeezadeh, A; Tafakhori, A, 2019
)
1.48
"Bumetanide treatments significantly enhanced cell proliferation and dendritic development of newborn DGCs after neonatal seizures, accompanied by the decreased seizure activity."( In vivo effects of bumetanide at brain concentrations incompatible with NKCC1 inhibition on newborn DGC structure and spontaneous EEG seizures following hypoxia-induced neonatal seizures.
Song, CG; Wang, S; Xiao, T; Zhang, XQ; Zhao, CS; Zhao, M; Zhu, G, 2015
)
1.47
"Bumetanide treatment significantly attenuates myelin basic protein loss and neuronal degeneration 7 d post-HI."( Chloride cotransporter NKCC1 inhibitor bumetanide protects against white matter injury in a rodent model of periventricular leukomalacia.
Hu, MY; Jackson, MC; Jantzie, LL; Jensen, FE; Maxwell, JR; Park, HK; Yu, J, 2015
)
1.41
"Bumetanide treatment significantly reduced KA-induced ictal activity in vivo and SLEs in vitro. "( Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
Maguire, J; Sivakumaran, S, 2016
)
3.32
"Bumetanide treatment increased ATP/Pi and PCr/Pi and ameliorated the declines in these values with insulin/saline treatment."( Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.
Anderson, SE; Glaser, N; O'Donnell, ME; Tancredi, DJ; Yuen, N, 2010
)
1.28
"Bumetanide-treated WT mice had a significant attenuation of AQP4 protein expression at 48 h post-MCAO compared to vehicle-treated WT mice."( Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4.
Adams, ME; Amiry-Moghaddam, M; Bhardwaj, A; Froehner, SC; Migliati, ER; Ottersen, OP, 2010
)
1.08
"Bumetanide treatment beyond six months in 11 patients indicated continued safety as well as efficacy."( Comparative efficacy and safety of bumetanide and furosemide in long-term treatment of edema due to congestive heart failure.
Barwolf-Gohlke, C; Dixon, DW; Gunnar, RM,
)
1.13
"In bumetanide-treated animals, mean sodium excretion rose to 12 per cent of the filtered load, while hydrochlorothiazide increased sodium excretion to 4 per cent of the filtered load."( Comparison of bumetanide and hydrochlorothiazide on renal potassium and hydrogen ion excretion.
Duchin, KL; Hutcheon, DE,
)
1.01
"In bumetanide-treated tubules, the secretagogue effects of DBcAMP are blocked."( Dibutyryl cAMP activates bumetanide-sensitive electrolyte transport in Malpighian tubules.
Baustian, MD; Beyenbach, KW; Hegarty, JL; Pannabecker, TL; Petzel, DH; Zhang, B, 1991
)
1.1
"Treatment with bumetanide during the first week post-CCI resulted in significant recovery of working and episodic memory as well as changes in theta band oscillations 1 month later."( Bumetanide induces post-traumatic microglia-interneuron contact to promote neurogenesis and recovery.
Blasco, E; Consumi, A; Dehapiot, B; Garcia, MS; Goubert, E; Guillemot, F; Hübner, CA; Laurin, J; Molinari, F; Pellegrino, C; Rivera, C; Tessier, M; Tian, L, 2023
)
2.69
"Treatment with bumetanide combined with ABA training may result in a better outcome in children with autism than ABA training alone."( A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism.
Du, L; Jia, F; Li, H; Shan, L; Staal, WG; Wang, B; Xu, Z, 2015
)
1.01
"Treatment with bumetanide did not significantly alter OX42 or GFAP intensity."( Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain.
Cohen, M; Glaser, N; Little, C; Lo, W; O'Donnell, M; Tancredi, D; Wulff, H, 2017
)
0.79
"Treatment with bumetanide, an NKCC inhibitor, had no effect on mechanical hypersensitivity seen in mice with EAE even though it reversed the changes in the levels of NKCC1 and KCC2."( The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
Kerr, B; Tenorio, G; Yousuf, MS; Zubkow, K, 2017
)
0.79
"Treatment with bumetanide may help diminish the adverse effects of initial treatment with insulin/saline."( Cerebral metabolic alterations in rats with diabetic ketoacidosis: effects of treatment with insulin and intravenous fluids and effects of bumetanide.
Anderson, SE; Glaser, N; O'Donnell, ME; Tancredi, DJ; Yuen, N, 2010
)
0.9
"Pretreatment with bumetanide (0.2-1 mg/kg i.p.) resulted in dose-dependent decrease of incidence of the tonic phase of generalized tonic-clonic seizures in 12-day-old rats only."( Age- and dose-specific anticonvulsant action of bumetanide in immature rats.
Mares, P, 2009
)
0.93
"Pretreatment with bumetanide, a blocker of NKCC-1, completely prevented the 30 μM α-chloralose-induced inhibition on eIPSC amplitude and Rf."( Different effects of α-chloralose on spontaneous and evoked GABA release in rat hippocampal CA1 neurons.
Akaike, N; Iwata, S; Matsuura, T; Ogawa, SK; Shin, MC; Wakita, M, 2011
)
0.69
"Pretreatment with bumetanide reduced 5-HT, 5-MeOT, and ICS 205-930 induced peak increases in SCC by 64, 75, and 58%, respectively."( ICS 205-930 reduces 5-methoxytryptamine-induced short-circuit current in stripped pig jejunum.
Hansen, MB, 1994
)
0.61
"Treatment with bumetanide or bromocriptine had no effect on the parameters studied."( Body water and weight in patients with premenstrual tension.
Andersch, B; Andersson, M; Hahn, L; Isaksson, B, 1978
)
0.6

Toxicity

ExcerptReferenceRelevance
" The method is based on the determination of the toxic dose (TD50) which causes a defined hearing loss in 50% of the animals tested."( Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide and ozolinone in the cat--a new approach to the problem of ototoxicity.
Göttl, KH; Klinke, R; Roesch, A, 1985
)
0.5
" Safety and adverse reactions during treatments are discussed."( Bumetanide: a new diuretic. Results of clinical efficacy and safety in patients with congestive heart failure.
Dhingra, RC; Handler, B; Rosen, KM,
)
1.57
" It is postulated that one important toxic effect of ammonia/ammonium is an increased demand for maintenance energy, caused by the need to maintain ion gradients over the cytoplasmic membrane."( Mechanisms of ammonia and ammonium ion toxicity in animal cells: transport across cell membranes.
Häggström, L; Martinelle, K, 1993
)
0.29
" Bumetanide could possibly be used in antifungal therapy to increase amphotericin B effectiveness doses without increasing its adverse effects."( Amphotericin B-induced apoptosis and cytotoxicity is prevented by the Na+, K+, 2Cl(-)-cotransport blocker bumetanide.
Grankvist, K; Henriksson, R; Marklund, L, 2000
)
1.43
"The antifungal antibiotic amphotericin B causes considerable toxic effects during clinical therapy."( Bumetanide annihilation of amphotericin B-induced apoptosis and cytotoxicity is due to its effect on cellular K+ flux.
Behnam-Motlagh, P; Grankvist, K; Henriksson, R; Marklund, L, 2001
)
1.75
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Seizure frequency and adverse events were assessed at every monthly visit."( A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Agah, E; Aghamollaii, V; Gharaylou, Z; Hadjighassem, M; Kebriaeezadeh, A; Tafakhori, A, 2019
)
0.76
" Five adverse events were detected in six patients."( A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Agah, E; Aghamollaii, V; Gharaylou, Z; Hadjighassem, M; Kebriaeezadeh, A; Tafakhori, A, 2019
)
0.76

Pharmacokinetics

Plasma concentrations of bumetanide accurately predicted several renal effects using a link model with similar pharmacodynamic parameters in each case. A physiologically-based pharmacokinetic (PBPK) model was developed for the prediction of bumatanide disposition in plasma and brain in adult and paediatric populations.

ExcerptReferenceRelevance
" The pharmacokinetic profile of bumetanide in eight human subjects receiving single 2-mg oral doses of the drug was elucidated using the radioimmunoassay."( Bumetanide: radioimmunoassay and pharmacokinetic profile in humans.
Alexander, K; Dixon, WR; Holazo, A; Jack, ML; Kaplan, SA; Liebman, A; Weinfeld, RE; Young, RL, 1976
)
1.98
"03 L/kg) and the elimination half-life (13."( Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation.
Fasules, JW; Kearns, GL; Taylor, BJ; Wells, TG, 1992
)
0.55
"The effects of pretreatment with the enzyme inducers, phenobarbital (PB) and 3-methylcholanthrene (3-MC), on the pharmacokinetic and pharmacodynamic parameters of bumetanide were examined in rats."( Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats.
Choi, YM; Jang, SH; Lee, MG; Lee, SH, 1991
)
0.69
" 6 A poor pharmacodynamic response and a reduced bumetanide excretion rate were observed for the patients with chronic renal failure, whereas with hepatic disease normal bumetanide excretion rates were observed with an impaired diuretic response."( The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
Auld, WH; Howes, CA; Marcantonio, LA; Murdoch, WR; Purohit, R; Skellern, GG, 1983
)
0.76
" Pharmacokinetic studies and the requisite pharmacologic evaluation on diuretics such as hydrochlorothiazide, spironolactone, ethacrynic acid and others should be done."( Pharmacokinetics of diuretics and methylxanthines in the neonate.
Aranda, JV; Sasyniuk, BI; Turmen, T, 1980
)
0.26
" Some pharmacokinetic parameters, such as the apparent volume of distribution at steady-state, mean residence time, and terminal half-life, remained relatively unchanged in all four treatments."( Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous bumetanide.
Lee, MG; Lee, SH; Yoon, WH, 1995
)
0.5
" dose, the pharmacokinetic parameters of bumetanide, such as t1/2 (21."( Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.
Kim, ND; Lee, MG; Lee, SH, 1994
)
0.82
" administration, the pharmacokinetic and pharmacodynamic parameters of bumetanide did not vary significantly between SHRs and the control Wistar rats."( Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats.
Han, KS; Kim, ND; Lee, MG; Lee, SH, 1993
)
0.78
" Some pharmacokinetic parameters of bumetanide were infusion time-dependent and it might be due to the saturable metabolism of bumetanide."( Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of bumetanide.
Lee, MG; Lee, MH; Ryoo, SH, 1993
)
0.77
" Data were evaluated by standard noncompartmental pharmacokinetic techniques."( Pharmacokinetics of bumetanide in critically ill infants.
Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996
)
0.62
" Pharmacokinetic parameter estimates (beta volume of distribution, volume of distribution at steady state, clearance, renal clearance, half-life, and mean residence time) were independent of the dose of bumetanide administered."( Pharmacokinetics of bumetanide in critically ill infants.
Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996
)
0.81
" The administered dose of bumetanide and age were positive determinants of bumetanide excretion rate and pharmacodynamic responses."( Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants.
Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996
)
0.82
"32 l/kg), and the harmonic mean half-life was 6-7 h (range of 4-19 h)."( The pharmacokinetics of bumetanide in the newborn infant.
Adams, JA; Goldberg, RN; Lopez-Samblas, AM; Modi, MW, 1997
)
0.6
" Plasma concentrations of bumetanide accurately predicted several renal effects using a link model with similar pharmacodynamic parameters in each case."( Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients.
Kearns, GL; Letzig, L; Marshall, JD; Wells, TG, 1998
)
0.87
"71 ml/min/kg)], terminal half-life (9."( Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects.
Kim, EJ; Lee, MG, 2001
)
0.56
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Because pharmacokinetic (PK) data are lacking in this population, who very often benefit from therapeutic cooling, which can modify the PK behavior of a drug, a PK study was conducted in term infants with seizures caused by hypoxic-ischemic encephalopathy."( Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures.
Blennow, M; Boylan, G; Chiron, C; Jullien, V; Marlow, N; Pons, G; Pressler, RM, 2016
)
0.68
" High plasma-protein binding, potentially high brain-tissue binding and putative efflux transporters including organic anion transporter 3 (OAT3) contribute to the poor pharmacokinetic profile of bumetanide."( In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide.
Boylan, GB; Cryan, JF; Donovan, MD; Griffin, BT; Schellekens, H, 2016
)
0.84
" A physiologically-based pharmacokinetic (PBPK) model was developed for the prediction of bumetanide disposition in plasma and brain in adult and paediatric populations."( Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate.
Abduljalil, K; Boylan, GB; Cryan, JF; Donovan, MD; Griffin, BT, 2018
)
0.93

Bioavailability

bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide) In rabbits after intranasal administration of eight formulations intended for use in acute situations, bioavailability was 70-80%. The extent of bioavailability from the tablet and oral solution dosage forms are equivalent.

ExcerptReferenceRelevance
" The extent of bioavailability was 81%, with a variability of 20% to 25% about the mean for both groups."( Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
Cook, JA; Cornish, LA; Hyneck, ML; Nicklas, JM; Smith, DE; Tankanow, RM, 1988
)
0.54
"A pharmacokinetic study was undertaken to determine the bioavailability of bumetanide in grossly oedematous patients."( Bioavailability of bumetanide in grossly oedematous patients.
Bailie, GR; Grennan, A; Waldek, S, 1987
)
0.83
" Although bioavailability was relatively consistent among the HS (0."( Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.
Berardi, RR; Hyneck, ML; Lau, HS; Smith, DE; Swartz, RD, 1986
)
0.53
") route, bumetanide was rapidly absorbed; bioavailability was 70-80%."( Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses.
Debackere, M; Delbeke, FT; Desmet, N; Stevens, M, 1986
)
0.96
" The extent of bioavailability of bumetanide from the tablet and oral solution dosage forms are equivalent, and the absolute bioavailability of the intramuscular and oral preparations are approximately 100 and 80%, respectively."( Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects.
Colburn, WA; Gustafson, JH; Holazo, AA; Parsonnet, M; Young, RL, 1984
)
0.87
" Consequently, bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide)."( Bumetanide and furosemide.
Anderson, S; Brater, DC; Burdette, A; Chennavasin, P; Day, B, 1983
)
2.06
" Open-circuit measurements of fluid absorption rate (Jv) and the net fluxes of 36Cl, 22Na, and 86Rb (K substitute) indicated that CO2-induced acidification stimulated NaCl and fluid absorption across the RPE."( Acidification stimulates chloride and fluid absorption across frog retinal pigment epithelium.
Edelman, JL; Lin, H; Miller, SS, 1994
)
0.29
" In congestive heart failure, the difference is greater between oral and intravenous doses than apparent from the bioavailability of the drugs."( [Loop diuretics. Rational pharmacotherapy].
Bülow, HH; Ladefoged, SD, 1993
)
0.29
"The bioavailability of bumetanide following the oral administration of tablets, or the rectal administration of either macrogol suppositories or suppositories with and without weak acids were evaluated in human subjects."( Bioavailability and diuretic effect of bumetanide following rectal administration of suppositories containing weak acids in human subjects.
Kenmotsu, H; Oda, K; Sekikawa, H; Shimode, Y; Takada, M; Yagi, N, 1993
)
0.87
" The bioavailability (absolute), expressed as the ratio of the area under the plasma concentration-time curve (AUC) following oral administration of bumetanide, was 39% that of intravenous administration."( Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits.
Kenmotsu, H; Oda, K; Sekikawa, H; Shimode, Y; Takada, M; Yagi, N, 1993
)
0.8
" The oral bioavailability of frusemide was significantly reduced by approximately 30% (75."( Effect of food on the absorption of frusemide and bumetanide in man.
Barron, W; Li Kam Wa, TC; McCrindle, JL; Prescott, LF, 1996
)
0.55
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The bioavailability of bumetanide in rabbits after intranasal administration of eight formulations intended for use in acute situations has been studied."( Intranasal administration of different liquid formulations of bumetanide to rabbits.
Bechgaard, E; Didriksen, E; Nielsen, HW; Sørensen, H; Twile, B, 2000
)
0.86
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" This could guarantee a faster absorption and a better bioavailability of the active principle."( Mechanochemical synthesis of bumetanide-4-aminobenzoic acid molecular cocrystals: a facile and green approach to drug optimization.
Berbenni, V; Bruni, G; Ferrara, C; Freccero, M; Girella, A; Grande, V; Maggi, L; Maietta, M; Marini, A; Milanese, C; Mustarelli, P, 2014
)
0.69
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The inhibition of dose-response curves by bumetanide, an inhibitor of NKCC1, as well as the expression of Nkcc1 mRNA and protein was greater in 18-week-old SHR than in age-matched WKY. The diuretic/saluretic effects of both formulations were measured in rabbits (n=8) for two days after dosing with 1mg/kg bumetsanide.

ExcerptRelevanceReference
" Furosemide had a similar effect on CI transport, but the dose-response curves of the two drugs were not parallel."( The mode of action of bumetanide: inhibition of chloride transport across the amphibian cornea.
Bentley, PJ; McGahan, MC; Yorio, T, 1977
)
0.57
" Extrapolation of the observed log dose-response curves provides one possible explanation for the relative potency (bumetanide: frusemide) of 20:1 reported when the drugs are used at high dosage in patients with renal failure."( Bumetanide and frusemide: a comparison of dose-response curves in healthy men.
Hettiarachchi, J; McInnes, GT; Ramsay, LE; Scott, P; Shelton, J, 1978
)
1.91
" The maximum depression of the EP (reduction to -30 to -40 mV) was obtained at a dosage of 30 mg/kg."( Reduction of the endocochlear potential by the new "loop" diuretic, bumetanide.
Ise, I; Kambayashi, J; Kawamoto, K; Kusakari, J,
)
0.37
" Dosage ranged from 1 mg to 3 mg daily depending on the patient's condition."( Bumetanide in congestive heart failure.
Augoustakis, D; Christensen, O; Kourouklis, C, 1976
)
1.7
"In a random crossover study in general practice, sixty patients with heart failure were given one week's maintenance treatment with the recommended dosage of Burinex K or Lasix+K."( Patient acceptability of two diuretic/potassium supplement preparations.
Bennion-Pedley, J; Donald, JF; Gould, CH; Lomas, DM; Postlethwaite, DL; Rivlin, R, 1976
)
0.26
" The dose-response analysis disclosed that bumetanide was 14 times as potent as furosemide."( Effect of bumetanide and furosemide on the thick ascending limb of Henle's loop of rabbits and rats perfused in vitro.
Imai, M, 1977
)
0.92
" Probenecid failed to displace the dose-response curve for bumetanide."( Hemodynamic and natriuretic effects of bumetanide and furosemide in the cat.
Friedman, PA; Roch-Ramel, F, 1977
)
0.77
"Intravenous dose-response data obtained from renal clearance studies in anesthetized dogs indicated that bumetanide was approximately 30-fold more potent than furosemide in enhancing sodium excretion."( A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog.
Cohen, MR; Hinsch, E; Kolis, SJ; Ryan, J; Schwartz, MA; Vergona, R, 1976
)
0.72
" Within this range the dose-response curve is steep and approximately linear."( [Dose-response relationship of bumetanide in healthy subjects].
Baethke, VR; Kampf, D, 1975
)
0.54
" In the presence of [Mg2+]o, substitution of foreign anions resulted in alterations in the agonist contractile dose-response curves; EC50s were increased whereas maximum tensions were depressed."( Interactions of magnesium and chloride ions on tone and contractility of vascular muscle.
Altura, BM; Altura, BT; Carella, A; Zhang, A, 1991
)
0.28
" Continuous administration will probably be useful in patients with severe CRI who have not achieved an adequate natriuresis or who show evidence of drug toxicity with standard diuretic dosing regimens."( Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy.
Brater, DC; Esparza, FA; Greene, PK; Rudy, DW; Voelker, JR, 1991
)
0.28
" The provocative concentration causing a 20% fall in FEV1 (logPC20) was calculated by linear interpolation of log dose-response curves."( Effect of inhaled furosemide and bumetanide on adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects.
Barnes, PJ; Chen-Worsdell, YM; Chung, KF; Fuller, RW; O'Connor, BJ, 1991
)
0.56
" The link between phospholipase C activation and these early events of the mitogenic response is demonstrated by the similarity of all dose-response curves for NaF and AlCl3 and by the common sensitivity of the four events to pertussis toxin."( Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin.
Chambard, JC; Paris, S; Pouysségur, J, 1987
)
0.27
" Cumulative dose-response data over the range 10(-7) to 10(-4) M luminal bumetanide were obtained in individual tubules in both KRB and KRH solutions."( Bumetanide inhibition of [CO2 + HCO3]-dependent and -independent equivalent electrical flux in renal cortical thick ascending limbs.
Friedman, PA, 1986
)
1.95
" Patients were assigned at random to receive one or other combination for 8 weeks, dosage being determined by the severity of the individual patient's condition (range 1 to 3 tablets frusemide/amiloride; 2 to 6 tablets bumetanide/potassium chloride)."( An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients.
Allman, S; Bailey, R; Crawford, RJ; Martin, A; Ramsay, F, 1988
)
0.68
" In the controlled double-blind oral study bumetanide was equipotent with furosemide at one fortieth the molar dosage and did not differ from furosemide with regards to its pattern of water and electrolyte excretion."( A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states.
Sagar, S; Sharma, BK; Sharma, PL; Wahi, PL, 1984
)
0.78
" The extent of bioavailability of bumetanide from the tablet and oral solution dosage forms are equivalent, and the absolute bioavailability of the intramuscular and oral preparations are approximately 100 and 80%, respectively."( Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects.
Colburn, WA; Gustafson, JH; Holazo, AA; Parsonnet, M; Young, RL, 1984
)
0.87
" Dose-response curves to noradrenaline administered as bolus doses or frequency-response curves from transmural arterial electrical stimulation were obtained."( Effect of bumetanide, frusemide and prostaglandin E2 on the isolated perfused kidney of rat and rabbit.
Foy, JM; Nuhu, SZ, 1984
)
0.67
" Increasing external chloride from 20 to 100 mM shifted the dose-response curve for the effect of bumetanide on co-transport toward higher concentrations of the drug."( Bumetanide inhibits (Na + K + 2Cl) co-transport at a chloride site.
Haas, M; McManus, TJ, 1983
)
1.93
"Analyses of bumetanide's dose-response relationship have been complicated by the hysteresis observed between the drug's urinary excretion rate and its sodium excretion."( Application of effect-compartment model to bumetanide-indomethacin interaction in dogs.
Fox, JL; Lau, HS; Smith, DE, 1983
)
0.91
" No differences between the dose-response curves of furosemide, bumetanide, or piretanide could be demonstrated."( Effect of diuretics on the tubuloglomerular feedback response.
Brunkhorst, R; Franke, H; Gutsche, HU; Müller-Ott, K; Niedermayer, W, 1984
)
0.51
" However, analysis of the dose-response curves between treatments I and II showed that sodium excretion was better correlated with bumetanide urinary excretion rate than with plasma concentration."( Determinants of bumetanide response in the dog: effect of probenecid.
Lau, HS; Smith, DE, 1983
)
0.82
" A dose-response relationship showed half-maximal inhibition of NaCl entry at a bumetanide concentration of 10(-9) M; complete inhibition of coupled NaCl movement occurred with as little as 10(-7) M bumetanide."( Bumetanide inhibition of NaCl transport by Necturus gallbladder.
Larson, M; Spring, KR, 1983
)
1.94
" The dose-response relationships of the N1 depressions to bumetanide and furosemide are parallel; those of the CM depressions are also parallel but have a much shallower slope than those of the N1 depressions."( Comparative acute cochlear toxicity of intravenous bumetanide and furosemide in the purebred beagle.
Brown, RD,
)
0.63
" The dosage of the drugs administered daily for three days was 1 to 2 mg bumetanide or 80 mg furosemide."( Clinical use of diuretics in congestive heart failure.
Hutcheon, D; Sandhu, RS; Vincent, ME,
)
0.36
" Despite few, well-designed studies using this method of administration in clinical practice, pharmacodynamic concepts support continuous infusion over bolus administration, including decreased dosage requirements, improved diuretic response and few adverse effects."( Continuous infusion of loop diuretics in the critically ill: a review of the literature.
Danziger, LH; Martin, SJ, 1994
)
0.29
" For all of the substrates tested the order of potency of these three inhibitors was the same (NPPB > furosemide > niflumate) and dose-response curves for the effect of these inhibitors on malaria-induced choline transport were similar to those for malaria-induced thymidine transport."( Transport of diverse substrates into malaria-infected erythrocytes via a pathway showing functional characteristics of a chloride channel.
Elford, BC; Ellory, JC; Horner, HA; Kirk, K; Newbold, CI, 1994
)
0.29
" After dosing horses intravenously with 5 mg ethacrynic acid per horse, the parent drug or its metabolites are detectable in urine for at least 8 hours."( Immunoassay detection of drugs in racing horses: detection of ethacrynic acid and bumetanide in equine urine by ELISA.
Blake, JW; Chang, SL; Goodman, JP; Henry, PA; Kwiatkowski, S; Stanley, S; Tai, HH; Watt, D; Wood, T; Woods, WE,
)
0.36
" Dose-response curves for urine flow rate and electrolyte excretion were similar between disease groups."( Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants.
Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996
)
0.52
" Time course patterns for urine flow rate and electrolyte excretion were similar for all dosage groups."( Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants.
Blumer, JL; Myers, CM; Sullivan, JE; Witte, MK; Yamashita, TS, 1996
)
0.59
" When eNPY and adrenaline (AD) were applied simultaneously, the effects were additive only at lower dosage (3 x 10(-8) M for eNPY, 3 x 10(-8) M for AD), but not at high dosage (10(-6) M eNPY, 10(-7) M AD)."( Effects of eel neuropeptide Y on ion transport across the seawater eel intestine.
Ando, M; Sugimoto, S; Uesaka, T; Yano, K, 1996
)
0.29
" Eight hours after dosing began, we administered approximately 80 mEq sodium intravenously and examined its excretion over 4 hours."( Role of duration of diuretic effect in preventing sodium retention.
Becker, PK; Brater, DC; Ferguson, JA; Gorski, JC; Rudy, DW; Sundblad, KJ, 1997
)
0.3
" These findings suggest higher dosing requirements and prolonged intervals as compared to adults."( The pharmacokinetics of bumetanide in the newborn infant.
Adams, JA; Goldberg, RN; Lopez-Samblas, AM; Modi, MW, 1997
)
0.6
" Important pharmacokinetic differences between adults and infants include a reduced clearance and prolonged half-life, that may cause accumulation of these agents to potentially toxic levels if dosing intervals are not adjusted."( The clinical pharmacology of loop diuretics in the pediatric patient.
Christensen, ML; Eades, SK, 1998
)
0.3
" When stimulated with phenylephrine, aortic smooth muscle from Nkcc1(+/+) and Nkcc1(-/-) mice exhibited no significant differences in maximum contractility and only moderate dose-response shifts."( Decreased blood pressure and vascular smooth muscle tone in mice lacking basolateral Na(+)-K(+)-2Cl(-) cotransporter.
Flagella, M; Lorenz, JN; Meyer, JW; Nieman, ML; Paul, RJ; Shull, GE; Sutliff, RL; Weber, CS, 2002
)
0.31
" The diuretic/saluretic effects of both formulations were measured in rabbits (n=8) for two days after dosing with 1mg/kg bumetanide."( A study of the pharmacodynamic differences between immediate and extended release bumetanide formulations.
Gerson, MC; Hamed, E; Millard, RW; Sakr, A, 2003
)
0.75
"5 to 200 mg), leaving no clear dosing recommendation."( Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.
Galatius, S; Gustafsson, F; Hildebrandt, PR; Rosenberg, J, 2005
)
0.33
" Genuine dose-response studies on combination therapy are not available and published studies involved adding one drug on top of 'usual treatment'."( Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction.
Bie, P; Christensen, NJ; Dalgaard, P; Frandsen, EK; Galløe, AM; Larsen, K; Nielsen, SL; Skagen, K, 2006
)
0.33
" ACh and Ca2+ dose-response studies demonstrated that NO3- solution does not shift their dose-response curves, and ATP depletion studies by dinitrophenol or anoxia demonstrated that exposure of NO3- solution prior to ATP depletion induced an enhanced initial phase followed by a sustained phase, whereas exposure of NO3- solution after ATP depletion induced only a sustained phase."( [Cl-]i modulation of Ca2+-regulated exocytosis in ACh-stimulated antral mucous cells of guinea pig.
Fujiwara, S; Kato, M; Katsu, K; Kubota, T; Nakahari, T; Shimamoto, C; Umegaki, E, 2007
)
0.34
" The inhibition of dose-response curves by bumetanide was much greater in SHR than in Wistar Kyoto (WKY) normotensive rats."( Promoter hypomethylation upregulates Na+-K+-2Cl- cotransporter 1 in spontaneously hypertensive rats.
Baek, I; Cho, HM; Hong, SH; Kim, IK; Lee, DY; Lee, HA; Seok, YM; Yang, E, 2010
)
0.62
" Based on pharmacokinetic studies with bumetanide, which showed extremely rapid elimination and low brain penetration of this drug in rats, bumetanide was administered systemically with different dosing protocols, including continuous intravenous infusion."( Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy.
Brandt, C; Heuchert, N; Löscher, W; Nozadze, M; Rattka, M, 2010
)
0.87
"The inhibition of dose-response curves by bumetanide, an inhibitor of NKCC1, as well as the expression of Nkcc1 mRNA and protein was comparable between 5-week-old SHR and age-matched WKY, but greater in 18-week-old SHR than in age-matched WKY."( Expression of Na+-K+ -2Cl- cotransporter 1 is epigenetically regulated during postnatal development of hypertension.
Cho, HM; Han, HS; Kim, HY; Kim, IK; Lee, HA, 2011
)
0.63
"Despite the widespread use of loop diuretics to treat acute decompensated heart failure (ADHF), robust data supporting their role and optimal dosing strategies are scarce."( A diuretic protocol increases volume removal and reduces readmissions among hospitalized patients with acute decompensated heart failure.
Barsuk, JH; Cohen, ER; Cotts, WG; Gordon, RA; Malkenson, D; Williams, MV; Yancy, CW,
)
0.13
" The proposed metric-weight loss indexed to diuretic dose-better captures a dose-response relationship."( Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014
)
0.4
" In turn, AVT had a dual effect on killifish opercular Isc: an immediate response (~3min) with Isc reduction in an inverted bell-shaped dose-response manner with higher current decrease (-22 μA⋅cm(-2)) at 10(-8) M AVT, and a sustained dose-dependent stimulation of Cl(-) secretion (stable up to 1h), with a threshold significant effect at 10(-8) M and maximal stimulation (~20 μA⋅cm(-2)) at 10(-6)M."( AVT and IT regulate ion transport across the opercular epithelium of killifish (Fundulus heteroclitus) and gilthead sea bream (Sparus aurata).
Fuentes, J; Mancera, JM; MartínezRodríguez, G; Martos-Sitcha, JA, 2015
)
0.42
" Dosing practices were described by rate (μg/kg/hr), duration (days), and previous diuretic use."( Bumetanide continuous infusions in critically ill pediatric patients.
Briceno-Medina, M; Chhim, RF; Figueroa, M; McCallister, KM; Rayburn, M; Shelton, CM, 2015
)
1.86
" Secondary objectives were to assess a dose-response relationship between bumetanide infusion rate and occurrence of myalgia and to investigate potential risk factors associated with bumetanide-induced myalgia."( Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure.
Chinaeke, EE; Cox, ZL; Lenihan, DJ; Lu, K; Merritt, TE; Xiong, L, 2019
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitorA EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of channel-conductance-controlling ATPase (EC 3.6.3.49, also known as cystic fibrosis conductance regulator, CFCR).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
amino acidA carboxylic acid containing one or more amino groups.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Bumetanide Action Pathway319

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.03160.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency28.10030.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency28.10030.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency23.51890.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
LuciferasePhotinus pyralis (common eastern firefly)Potency11.99550.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency46.40210.100020.879379.4328AID588456
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency24.14540.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency2.12010.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.10210.000214.376460.0339AID720691
IDH1Homo sapiens (human)Potency12.99530.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency19.95260.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency21.58550.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency6.15900.00419.984825.9290AID504444; AID720524
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency6.30960.65619.452025.1189AID927
gemininHomo sapiens (human)Potency0.14580.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency100.00000.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency23.44510.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency7.26800.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency3.16230.015812.3113615.5000AID1461
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency6.30961.584913.004325.1189AID927
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki5.50001.60005.744010.0000AID681388
Carbonic anhydrase 12Homo sapiens (human)Ki18.32420.00021.10439.9000AID1798598
Bile salt export pumpHomo sapiens (human)IC50 (µMol)264.80000.11007.190310.0000AID1443980; AID1449628; AID1473738
Carbonic anhydrase 1Homo sapiens (human)Ki18.32420.00001.372610.0000AID1798598
Carbonic anhydrase 2Homo sapiens (human)Ki18.32420.00000.72369.9200AID1798598
Carbonic anhydrase 3Homo sapiens (human)Ki18.32420.00022.010210.0000AID1798598
Carbonic anhydrase 4Homo sapiens (human)Ki18.32420.00021.97209.9200AID1798598
Carbonic anhydrase 6Homo sapiens (human)Ki18.32420.00011.47109.9200AID1798598
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki18.32420.00001.27259.9000AID1798598
Carbonic anhydrase 7Homo sapiens (human)Ki18.32420.00021.37379.9000AID1798598
Solute carrier family 12 member 2Homo sapiens (human)IC50 (µMol)0.80000.80000.80000.8000AID1919674
Carbonic anhydrase 9Homo sapiens (human)Ki18.32420.00010.78749.9000AID1798598
Carbonic anhydrase 13Mus musculus (house mouse)Ki18.32420.00021.39749.9000AID1798598
Carbonic anhydrase 14Homo sapiens (human)Ki18.32420.00021.50999.9000AID1798598
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki18.32420.00001.34129.9700AID1798598
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Kinact0.02110.00300.66749.6000AID328983
Carbonic anhydrase 1Homo sapiens (human)Kinact4.93000.01000.93878.6000AID328974
Carbonic anhydrase 2Homo sapiens (human)Kinact6.98000.00300.794610.0000AID328975
Carbonic anhydrase 4Homo sapiens (human)Kinact0.30300.07402.39348.5900AID328977
Carbonic anhydrase 6Homo sapiens (human)Kinact3.89000.00090.72615.3000AID328980
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Kinact0.70000.02000.85809.4000AID328978
Carbonic anhydrase 7Homo sapiens (human)Kinact0.06200.00020.28525.7300AID328981
Carbonic anhydrase 9Homo sapiens (human)Kinact0.02580.00500.31976.6700AID328982
Carbonic anhydrase 13Mus musculus (house mouse)Kinact2.57000.01300.56698.2300AID328984
Carbonic anhydrase 14Homo sapiens (human)Kinact0.25000.00021.44958.5900AID328985
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Kinact0.15900.00900.92319.0400AID328979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (120)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
cell volume homeostasisSolute carrier family 12 member 2Homo sapiens (human)
maintenance of blood-brain barrierSolute carrier family 12 member 2Homo sapiens (human)
intracellular sodium ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
cell volume homeostasisSolute carrier family 12 member 2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwaySolute carrier family 12 member 2Homo sapiens (human)
intracellular potassium ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
intracellular chloride ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
maintenance of blood-brain barrierSolute carrier family 12 member 2Homo sapiens (human)
negative regulation of vascular wound healingSolute carrier family 12 member 2Homo sapiens (human)
regulation of spontaneous synaptic transmissionSolute carrier family 12 member 2Homo sapiens (human)
positive regulation of aspartate secretionSolute carrier family 12 member 2Homo sapiens (human)
regulation of matrix metallopeptidase secretionSolute carrier family 12 member 2Homo sapiens (human)
monoatomic ion transportSolute carrier family 12 member 2Homo sapiens (human)
cell volume homeostasisSolute carrier family 12 member 2Homo sapiens (human)
hyperosmotic responseSolute carrier family 12 member 2Homo sapiens (human)
T cell chemotaxisSolute carrier family 12 member 2Homo sapiens (human)
transepithelial chloride transportSolute carrier family 12 member 2Homo sapiens (human)
cellular response to potassium ionSolute carrier family 12 member 2Homo sapiens (human)
positive regulation of cell volumeSolute carrier family 12 member 2Homo sapiens (human)
transepithelial ammonium transportSolute carrier family 12 member 2Homo sapiens (human)
ammonium transmembrane transportSolute carrier family 12 member 2Homo sapiens (human)
inorganic anion import across plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
inorganic cation import across plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
sodium ion import across plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 12 member 2Homo sapiens (human)
chloride transmembrane transportSolute carrier family 12 member 2Homo sapiens (human)
potassium ion import across plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
cellular response to chemokineSolute carrier family 12 member 2Homo sapiens (human)
sodium ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
chloride ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 12 member 2Homo sapiens (human)
potassium ion homeostasisSolute carrier family 12 member 2Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
protein bindingSolute carrier family 12 member 2Homo sapiens (human)
sodium:potassium:chloride symporter activitySolute carrier family 12 member 2Homo sapiens (human)
ammonium transmembrane transporter activitySolute carrier family 12 member 2Homo sapiens (human)
potassium ion transmembrane transporter activitySolute carrier family 12 member 2Homo sapiens (human)
chloride:monoatomic cation symporter activitySolute carrier family 12 member 2Homo sapiens (human)
protein kinase bindingSolute carrier family 12 member 2Homo sapiens (human)
metal ion transmembrane transporter activitySolute carrier family 12 member 2Homo sapiens (human)
protein-folding chaperone bindingSolute carrier family 12 member 2Homo sapiens (human)
Hsp90 protein bindingSolute carrier family 12 member 2Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
membraneSolute carrier family 12 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
lateral plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
cytoplasmic vesicle membraneSolute carrier family 12 member 2Homo sapiens (human)
cell projection membraneSolute carrier family 12 member 2Homo sapiens (human)
cell projectionSolute carrier family 12 member 2Homo sapiens (human)
neuron projectionSolute carrier family 12 member 2Homo sapiens (human)
neuronal cell bodySolute carrier family 12 member 2Homo sapiens (human)
cell bodySolute carrier family 12 member 2Homo sapiens (human)
cell body membraneSolute carrier family 12 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 12 member 2Homo sapiens (human)
cell peripherySolute carrier family 12 member 2Homo sapiens (human)
extracellular vesicleSolute carrier family 12 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 12 member 2Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (253)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID328975Inhibition of human full length carbonic anhydrase 22008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1145150Saluretic activity in dog assessed as urinary excretion of potassium level at 0.1 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1145151Saluretic activity in dog assessed as urinary excretion of chloride level at 0.1 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1148119Diuretic effect in mongrel dog assessed as urinary excretion of water at 0.25 mg/kg, iv after 3 hrs (Rvb = 0.93 +/- 0.35 ml/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID1148149Diuretic effect in mongrel dog assessed as urinary excretion of Na+ at 0.01 mg/kg, po after 3 hrs (Rvb = 0.10 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID599064Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID5985271-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID328976Inhibition of human full length carbonic anhydrase 32008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1132965High-ceiling diuretic activity in Wistar rat assessed as drug to urea ratio to increase Na+ level in urine at 50 mg/kg, po measured for 5 hrs by flame photometric analysis (Rvb = 0.47 +/- 0.07 no unit)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
8-Carboxy-6-sulfamyldibenz[b,f][1,4]oxazepines and -thiazepines as potential high-ceiling diuretics.
AID328984Inhibition of mouse full length carbonic anhydrase 132008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1817430Inhibition of NKCC1 (unknown origin) transfected in HEK293 cells expressing mbYFPQS plasmid assessed as reduction in Cl- influx at 100 uM incubated for 30 mins by fluorescence multiplate reader analysis relative to control
AID679338TP_TRANSPORTER: uptake in Ntcp-expressing HPCT-1E3 cells1996European journal of cell biology, May, Volume: 70, Issue:1
Functional characterization of the hepatic sodium-dependent taurocholate transporter stably transfected into an immortalized liver-derived cell line and V79 fibroblasts.
AID680237TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996Biochimica et biophysica acta, Apr-19, Volume: 1300, Issue:2
Bumetanide is not transported by the Ntcp or by the oatp: evidence for a third organic anion transporter in rat liver cells.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1817428Metabolic stability in mouse liver microsomes assessed as half life at 5 uM
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1145162Saluretic activity in dog assessed as urinary excretion of potassium level at 0.1 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1145149Saluretic activity in dog assessed as urinary excretion of sodium level at 0.1 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID173783Natriuretic potency was evaluated as oral dose required to produce an excretion of 2 mequiv of Na+/Kg of rat body weight, ED2 value based on N=4 rats/dose1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
[(Aminomethyl)aryloxy]acetic acid esters. A new class of high-ceiling diuretics. 4. Substituted 6,7-dichloro-2,3-dihydrobenzofurans derived by ring annelation.
AID1145165Diuretic activity in dog assessed as urine volume measured in water at 0.01 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1145163Saluretic activity in dog assessed as urinary excretion of chloride level at 0.1 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1145160Diuretic activity in dog assessed as urine volume measured in water at 0.1 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID5985261-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1145168Saluretic activity in dog assessed as urinary excretion of chloride level at 0.01 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1145148Diuretic activity in dog assessed as urine volume measured in water at 0.1 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1148137Diuretic effect in mongrel dog assessed as urinary excretion of Cl- at 0.25 mg/kg, iv after 3 hrs (Rvb = 0.08 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1145140Diuretic activity in dog assessed as urine volume measured in water at 0.25 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID59305Natriuretic potency was evaluated as oral dose required to produce an excretion of 2 mequiv of Na+/Kg of dog body weight, ED5 value based on N=2 dogs/dose1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
[(Aminomethyl)aryloxy]acetic acid esters. A new class of high-ceiling diuretics. 4. Substituted 6,7-dichloro-2,3-dihydrobenzofurans derived by ring annelation.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID328980Inhibition of human full length carbonic anhydrase 62008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681388TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1.
AID1145141Saluretic activity in dog assessed as urinary excretion of sodium level at 0.25 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1145167Saluretic activity in dog assessed as urinary excretion of potassium level at 0.01 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID328978Inhibition of human full length carbonic anhydrase 5A2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID328974Inhibition of human full length carbonic anhydrase 12008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1148161Diuretic effect in mongrel dog assessed as urinary excretion of Cl- at 0.01 mg/kg, po after 3 hrs (Rvb = 0.08 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID1148155Diuretic effect in mongrel dog assessed as urinary excretion of K+ at 0.01 mg/kg, po after 3 hrs (Rvb = 0.16 +/- 0.01 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588965Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT32010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID679526TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Bumetamide: 100 uM) in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1148131Diuretic effect in mongrel dog assessed as urinary excretion of K+ at 0.25 mg/kg, iv after 3 hrs (Rvb = 0.16 +/- 0.01 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1817437Diuretic activity in wild type mouse assessed as increase in urine volume at 0.6 mg/kg, ip measured after 2 hrs
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1132964High-ceiling diuretic activity in Wistar rat assessed as drug to urea ratio to cause diuresis at 50 mg/kg, po measured for 5 hrs (Rvb = 0.44 +/- 0.05 no unit)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
8-Carboxy-6-sulfamyldibenz[b,f][1,4]oxazepines and -thiazepines as potential high-ceiling diuretics.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID328982Inhibition of human catalytic domain carbonic anhydrase 92008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145143Saluretic activity in dog assessed as urinary excretion of chloride level at 0.25 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1169140Retention time of the compound by EPSA supercritical fluid chromatography2014ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10
EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID328983Inhibition of human catalytic domain carbonic anhydrase 122008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID680199TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Bumetanide: 500 uM) in Xenopus laevis oocytes2000The Journal of biological chemistry, Feb-11, Volume: 275, Issue:6
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
AID1148135Diuretic effect in mongrel dog assessed as urinary excretion of water at 0.01 mg/kg, po after 3 hrs (Rvb = 0.93 +/- 0.35 ml/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID679682TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, Bumetanide: 500 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328981Inhibition of human full length carbonic anhydrase 72008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328979Inhibition of human full length carbonic anhydrase 5B2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1148125Diuretic effect in mongrel dog assessed as urinary excretion of Na+ at 0.25 mg/kg, iv after 3 hrs (Rvb = 0.10 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1145142Saluretic activity in dog assessed as urinary excretion of potassium level at 0.25 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID328977Inhibition of human full length carbonic anhydrase 42008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1817431Kinetic aqueous solubility of compound in PBS at pH 7.4 at 250 uM
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID681542TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 17 uM, Bumetanide: 500 uM) in Xenopus laevis oocytes1991Proceedings of the National Academy of Sciences of the United States of America, Dec-01, Volume: 88, Issue:23
Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1148121Diuretic effect in mongrel dog assessed as urinary excretion of water at 0.1 mg/kg, iv after 3 hrs (Rvb = 0.93 +/- 0.35 ml/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1817432Inhibition of NKCC1 in mouse primary hippocampal neurons assessed as reduction of Ca2+ uptake at 10 uM incubated for 15 mins by Fluo-4AM dye based fluorescence analysis relative to control
AID681437TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, Bumetanide: 1000 uM) in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID1817433Inhibition of NKCC1 in mouse primary hippocampal neurons assessed as reduction of Ca2+ uptake at 100 uM incubated for 15 mins by Fluo-4AM dye based fluorescence analysis relative to control
AID328985Inhibition of human full length carbonic anhydrase 142008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1148127Diuretic effect in mongrel dog assessed as urinary excretion of Na+ at 0.1 mg/kg, iv after 3 hrs (Rvb = 0.10 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID1817438Diuretic activity in Ts65Dn mouse assessed as increase in urine volume at 0.6 mg/kg, ip measured after 2 hrs
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1148133Diuretic effect in mongrel dog assessed as urinary excretion of K+ at 0.1 mg/kg, iv after 3 hrs (Rvb = 0.16 +/- 0.01 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148139Diuretic effect in mongrel dog assessed as urinary excretion of Cl- at 0.1 mg/kg, iv after 3 hrs (Rvb = 0.08 +/- 0.02 mequiv/kg)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Aminobenzoic acid diuretics. 9. 3,4-Disubstituted 5-acylaminobenzoic acids and related compounds.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679366TP_TRANSPORTER: inhibition of Salicylate uptake (salicylate: 1 uM, Bumetanide: 1000 uM) in Xenopus laevis oocytes1998FEBS letters, Jun-12, Volume: 429, Issue:2
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID1132966High-ceiling diuretic activity in Wistar rat assessed as drug to urea ratio to increase K+ level in urine at 50 mg/kg, po measured for 5 hrs by flame photometric analysis (Rvb = 0.57 +/- 0.08 no unit)1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
8-Carboxy-6-sulfamyldibenz[b,f][1,4]oxazepines and -thiazepines as potential high-ceiling diuretics.
AID1145161Saluretic activity in dog assessed as urinary excretion of sodium level at 0.1 mg/kg, po after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID1817429Inhibition of NKCC1 (unknown origin) transfected in HEK293 cells expressing mbYFPQS plasmid assessed as reduction in Cl- influx at 10 uM incubated for 30 mins by fluorescence multiplate reader analysis relative to control
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1145166Saluretic activity in dog assessed as urinary excretion of sodium level at 0.01 mg/kg, iv after 3 hrs1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
Aminobenzioc acid diuretics. 8.(2) 3, 4-Disubstituted 5-methylsulfonylbenzioc acids and related compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID681229TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Bumetanide: 5 uM) in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346941Human Basolateral Na-K-Cl symporter (SLC12 family of cation-coupled chloride transporters)2002Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 365, Issue:3
Rat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs.
AID1346968Human Kidney-specific Na-K-Cl symporter (SLC12 family of cation-coupled chloride transporters)2002Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 365, Issue:3
Rat NKCC2/NKCC1 cotransporter selectivity for loop diuretic drugs.
AID1345073Human GPR35 (Class A Orphans)2012Pharmacology, , Volume: 89, Issue:1-2
GPR35 is a target of the loop diuretic drugs bumetanide and furosemide.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1798598CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,949)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990532 (27.30)18.7374
1990's622 (31.91)18.2507
2000's387 (19.86)29.6817
2010's324 (16.62)24.3611
2020's84 (4.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.94 (24.57)
Research Supply Index7.69 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index199.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (106.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials150 (7.38%)5.53%
Reviews66 (3.25%)6.00%
Case Studies40 (1.97%)4.05%
Observational0 (0.00%)0.25%
Other1,777 (87.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease [NCT03899324]Phase 240 participants (Anticipated)Interventional2019-04-26Recruiting
Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure. DIVINE STUDY [NCT03709160]Phase 440 participants (Anticipated)Interventional2018-10-15Recruiting
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure [NCT02546583]Phase 1458 participants (Actual)Interventional2015-08-31Completed
A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects [NCT05503511]Phase 150 participants (Actual)Interventional2022-10-20Completed
A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol [NCT02582476]Phase 212 participants (Anticipated)Interventional2015-01-31Terminated(stopped due to Slow enrolment and end of funding)
Diuretic/Cool Dialysate Trial [NCT02593526]11 participants (Actual)Interventional2017-01-31Completed
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safe [NCT03715153]Phase 3211 participants (Actual)Interventional2018-10-04Terminated(stopped due to The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified.)
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects [NCT00930865]Phase 142 participants (Actual)Interventional2009-07-31Completed
Effects of Fluid Balance Control in Critically Ill Patients: A Multicenter Randomized Study [NCT02765009]1,411 participants (Actual)Interventional2016-06-01Completed
Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures [NCT00830531]Phase 143 participants (Actual)Interventional2010-01-31Completed
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial [NCT03923933]Phase 234 participants (Actual)Interventional2019-06-18Completed
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children [NCT04766177]Phase 380 participants (Anticipated)Interventional2021-01-01Recruiting
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD [NCT05171686]Phase 446 participants (Anticipated)Interventional2023-02-01Recruiting
A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 W [NCT03715166]Phase 3211 participants (Actual)Interventional2018-09-24Terminated(stopped due to The 6-month efficacy analysis did not show any significant difference between bumetanide versus placebo in the treatment of ASD in the overall studied population. No unexpected safety concerns were identified.)
Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children [NCT01078714]Phase 360 participants (Actual)Interventional2010-03-31Completed
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction: A Pilot Trial [NCT05129722]Phase 430 participants (Anticipated)Interventional2022-10-01Recruiting
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment [NCT05411991]Phase 4104 participants (Anticipated)Interventional2022-06-12Recruiting
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial [NCT06036914]Phase 220 participants (Anticipated)Interventional2023-11-27Enrolling by invitation
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus: A Pilot Trial [NCT04697485]Phase 40 participants (Actual)Interventional2021-01-08Withdrawn(stopped due to Enrollment and funding challenges)
Bumetanide Has a More Favourable Effect on Insulin Resistance Than Furosemide in Patients With Heart Failure - A Pilot Study [NCT00372762]Phase 30 participants (Actual)Interventional2011-01-31Withdrawn(stopped due to Due to changes within the research program this study is not feasible at this time)
Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology : Multicenter and Double Blind-study With Randomized Parallel Group, Against Placebo. [NCT02947880]Phase 20 participants (Actual)Interventional2016-12-31Withdrawn(stopped due to the recently feasibility study shows that the number of patients is insufficient in the centers)
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease. [NCT06052163]Phase 240 participants (Anticipated)Interventional2023-10-15Not yet recruiting
NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent [NCT01434225]Phase 1/Phase 214 participants (Actual)Interventional2011-08-31Completed
Mechanisms of Diuretic Resistance in Heart Failure [NCT05323487]75 participants (Anticipated)Interventional2022-06-01Recruiting
Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure [NCT01973335]Phase 434 participants (Actual)Interventional2013-11-30Completed
A Randomized Controlled Pilot Study for Assessment of Coronary Flow Reserve With Cardiac PET Imaging in Acute Decompensated Heart Failure Patients Treated With Diuretics Versus Ultrafiltration [NCT01457053]4 participants (Actual)Interventional2011-11-30Terminated(stopped due to Population not available for enrollment)
A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder:a Randomized Double-blind Placebo-controlled Trial [NCT03156153]Phase 2120 participants (Actual)Interventional2017-05-24Completed
Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma [NCT03107416]Phase 1/Phase 230 participants (Actual)Interventional2017-04-05Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01973335 (7) [back to overview]Acetazolamide Arm: Natriuresis 24 h
NCT01973335 (7) [back to overview]NT-proBNP Change After 72 h
NCT01973335 (7) [back to overview]Number of Participants With Worsening Renal Function
NCT01973335 (7) [back to overview]Peak Plasma Aldosterone Concentration After 72 h
NCT01973335 (7) [back to overview]Peak Plasma Renin Activity After 72 h
NCT01973335 (7) [back to overview]Persistent Renal Impairment
NCT01973335 (7) [back to overview]Spironolactone Arm: Incidence of Hypo- (Serum Potassium <3.5 mmol/L) or Hyperkalemia (Serum Potassium >5.0 mmol/L)
NCT03715153 (7) [back to overview]Childhood Autism Rating Scale, Second Edition (CARS2) Total Raw Score
NCT03715153 (7) [back to overview]Clinical Global Impression - Global Improvement (CGI-I) Score
NCT03715153 (7) [back to overview]Number of Patients With Abnormalities in 12-leads Electrocardiogram (ECG) Parameters
NCT03715153 (7) [back to overview]Paediatric Quality of Life Inventory (PedsQL) Questionnaire
NCT03715153 (7) [back to overview]Social Responsiveness Scale, Second Edition (SRS-2) Total Raw Score
NCT03715153 (7) [back to overview]Vineland Adaptative Behaviour Scale II (VABS II)
NCT03715153 (7) [back to overview]Number of Participants Experiencing at Least 1 Treatment Emergent Adverse Event (TEAE)
NCT03923933 (7) [back to overview]Change in Diastolic Blood Pressure
NCT03923933 (7) [back to overview]Change in Extracellular Water
NCT03923933 (7) [back to overview]Change in Extracellular Water / Total Body Water Ratio
NCT03923933 (7) [back to overview]Change in Mean Arterial Pressure
NCT03923933 (7) [back to overview]Change in Systolic Blood Pressure
NCT03923933 (7) [back to overview]Change in the Fractional Excretion of Sodium
NCT03923933 (7) [back to overview]Change in Total Body Water

Acetazolamide Arm: Natriuresis 24 h

For the acetazolamide arm of the study, the primary end-point is total natriuresis after 24 h (mmol). To assess this, urine is collected for 24 h after the first administration of diuretics according to the study protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L). Subsequently, patients receiving acetazolamide and low-dose loop diuretics (both the groups with and without upfront spironolactone together) are compared to patients not receiving acetazolamide but high-dose loop diuretics instead (both the groups with or without upfront spironolactone together) (NCT01973335)
Timeframe: 24h

Interventionmmol (Mean)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone324
High-dose Loop Diuretics, Upfront Spironolactone300
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone211
High-dose Loop Diuretics, no Spironolactone190

[back to top]

NT-proBNP Change After 72 h

Relative NT-proBNP change (%) after 72 h compared to baseline. (NCT01973335)
Timeframe: 72h

Interventionpercentage change from baseline (Mean)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone-20
High-dose Loop Diuretics, Upfront Spironolactone-11
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone-3
High-dose Loop Diuretics, no Spironolactone-6

[back to top]

Number of Participants With Worsening Renal Function

Worsening renal function is defined as a rise in serum creatine >0.3 mg/dL or a >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula compared to baseline at any time point before 72 h. Serum creatinine values are assessed at three consecutive mornings after study inclusion. (NCT01973335)
Timeframe: 72h

InterventionParticipants (Count of Participants)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone2
High-dose Loop Diuretics, Upfront Spironolactone0
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone3
High-dose Loop Diuretics, no Spironolactone0

[back to top]

Peak Plasma Aldosterone Concentration After 72 h

At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma aldosterone levels. The highest value will constitute the peak plasma aldosterone concentration (ng/L). (NCT01973335)
Timeframe: 72h

Interventionng/L (Median)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone196
High-dose Loop Diuretics, Upfront Spironolactone234
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone302
High-dose Loop Diuretics, no Spironolactone204

[back to top]

Peak Plasma Renin Activity After 72 h

At three consecutive mornings after study inclusion, blood samples will be taken to assess plasma renin activity. The highest value will constitute the peak plasma renin activity (ng/mL/h). (NCT01973335)
Timeframe: 72h

Interventionµg/L/h (Median)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone3.8
High-dose Loop Diuretics, Upfront Spironolactone5.0
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone12.0
High-dose Loop Diuretics, no Spironolactone2.5

[back to top]

Persistent Renal Impairment

Persistent renal impairment is defined as a persistently elevated serum creatine >0.3mg/dL or >20% decrease in estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, above the baseline value of the patient and will be assessed on a scheduled follow-up appointment 4 weeks after hospital discharge. (NCT01973335)
Timeframe: 4 weeks after hospital discharge

InterventionParticipants (Count of Participants)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone3
High-dose Loop Diuretics, Upfront Spironolactone1
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone0
High-dose Loop Diuretics, no Spironolactone1

[back to top]

Spironolactone Arm: Incidence of Hypo- (Serum Potassium <3.5 mmol/L) or Hyperkalemia (Serum Potassium >5.0 mmol/L)

For the spironolactone arm of the study, the primary end-point is the incidence of either hypo- (serum potassium <3.5 mmol/L) or hyperkalemia (serum potassium >5.0 mmol/L) at any of 3 morning blood samples at consecutive days after randomization. Patients receiving upfront spironolactone (both the group receiving acetazolamide+low dose loop diuretics and the group receiving high-dose loop diuretic therapy) are compared with them receiving no spironolactone (both the group receiving acetazolamide+low dose loop diuretics and the group receiving high-dose loop diuretic therapy). (NCT01973335)
Timeframe: 72h

InterventionParticipants (Count of Participants)
Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone1
High-dose Loop Diuretics, Upfront Spironolactone2
Acetazolamide/Low-dose Loop Diuretics, no Spironolactone5
High-dose Loop Diuretics, no Spironolactone2

[back to top]

Childhood Autism Rating Scale, Second Edition (CARS2) Total Raw Score

"The CARS2 total raw score range from 15 to 60. This scale is a behaviour rating scale intended to diagnose autism. A total score of 15 indicates that an individual behaviour is within normal limits, whereas a value of 60 indicates that the individual's behaviour is severly abnormal.~In term of change from baseline, the greater the mean value decreases, the better it is." (NCT03715153)
Timeframe: Change from baseline to Week 26

Interventionscore on a scale (Mean)
BUMETANIDE (S95008)-3.66
PLACEBO-3.88

[back to top]

Clinical Global Impression - Global Improvement (CGI-I) Score

"Scale which assesses the severity of the illness and the global improvement of the patient under study treatment.~It ranges from 1 (normal) through to 7 (amongst the most severely ill patients)." (NCT03715153)
Timeframe: At Week 26

Interventionscore on a scale (Mean)
BUMETANIDE (S95008)2.9
PLACEBO3.1

[back to top]

Number of Patients With Abnormalities in 12-leads Electrocardiogram (ECG) Parameters

"Number of patients with clinically significant ECG abnormalities~The 12-lead electrocardiogram (ECG) is a medical test that is recorded using leads, or nodes, attached to the body. Electrocardiograms (ECGs), capture the electrical activity of the heart and transfer it to graphed paper where abnormalities are reported and interpretated by the cardiologist." (NCT03715153)
Timeframe: Week 26

InterventionParticipants (Count of Participants)
BUMETANIDE (S95008)0
PLACEBO0

[back to top]

Paediatric Quality of Life Inventory (PedsQL) Questionnaire

It represents the assessment of parent/legal representative perception of patient health related quality of life The values of the questionnaire range from 0 to 100. Higher scores indicate better HRQOL (Health-Related Quality of Life) (NCT03715153)
Timeframe: Change from baseline to week 26

Interventionscore on a scale (Mean)
BUMETANIDE (S95008)5.87
PLACEBO5.47

[back to top]

Social Responsiveness Scale, Second Edition (SRS-2) Total Raw Score

"The SRS-2 total raw score serves as an index of severity of social deficits in the autism spectrum.~The total raw score ranges from 65 to 260. A value of 65 represents no symptoms disorders, a value of 260 represents a severe autism spectrum disorder.~In terms of change from baseline, the greater the mean value decreases, the better it is." (NCT03715153)
Timeframe: Change from baseline to Week 26

Interventionscore on a scale (Mean)
BUMETANIDE (S95008)-16.3
PLACEBO-18.7

[back to top]

Vineland Adaptative Behaviour Scale II (VABS II)

Scale designated to measure adaptative behaviour The scale for behaviour ranges from 1 to 67. The more the score decreases, the better it is. (NCT03715153)
Timeframe: Change from baseline to Week 26

Interventionscore on a scale (Mean)
BUMETANIDE (S95008)1.1
PLACEBO0.7

[back to top]

Number of Participants Experiencing at Least 1 Treatment Emergent Adverse Event (TEAE)

(NCT03715153)
Timeframe: through week 52

,
InterventionParticipants (Count of Participants)
Reported during the double-blind period (Week 0 - 26)Reported during the open-label period (Week 26-52)
BUMETANIDE (S95008) Followed by Open-Label S9500810384
PLACEBO Followed by Open-Label S950089681

[back to top]

Change in Diastolic Blood Pressure

(NCT03923933)
Timeframe: Change from Basal to day 28

InterventionmmHg (Mean)
Placebo-3.4
Treatment Grup-13.5

[back to top]

Change in Extracellular Water

Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Interventionlitres (Mean)
Placebo-0.15
Treatment Grup2.55

[back to top]

Change in Extracellular Water / Total Body Water Ratio

Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Interventionpercentage of ECW/TBW (Mean)
Placebo-0.24
Treatment Grup-2.92

[back to top]

Change in Mean Arterial Pressure

decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28

InterventionmmHg (Mean)
Placebo-5.4
Treatment Grup-18.1

[back to top]

Change in Systolic Blood Pressure

(NCT03923933)
Timeframe: Change from Basal to day 28

InterventionmmHg (Mean)
Placebo-10
Treatment Grup-26.1

[back to top]

Change in the Fractional Excretion of Sodium

Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28

Interventionpercentage of sodium excreted (Mean)
Placebo-0.348
Treatment Grup0.598

[back to top]

Change in Total Body Water

Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28

Interventionlitres (Mean)
Placebo-0.075
Treatment Grup-4.36

[back to top]